GE HealthCare to acquire Sofie Biosciences for $945 million

GE HealthCare announced on 5 October 2026 that it will acquire Sofie Biosciences for $945 million in cash, expanding its presence in the growing radiopharmaceuticals market. The deal, expected to close in the first half of 2027, grants GE HealthCare U.S. rights to FAPI-74, a late-stage experimental PET imaging agent for cancer detection. Sofie Biosciences, owned by Trilantic, will continue manufacturing for existing customers.

Growth in the radiopharmaceuticals market

• ▪The acquisition of Sofie Biosciences by GE HealthCare is part of a broader trend of rising dealmaking in the radiopharmaceuticals industry, which includes Curium's August 2026 deal of up to $8 billion for Lantheus
• ▪The radiopharmaceuticals market is growing as companies seek to capitalize on the increasing use of radioactive drugs in cancer care, heart disease, and Alzheimer's

Impact on GE HealthCare

• ▪The acquisition of Sofie Biosciences announced on 5 October 2026 bolsters GE HealthCare's pharmaceutical diagnostics arm by adding products used with its imaging systems and increasing its exposure to the radiopharmaceuticals market
• ▪The acquisition of Sofie Biosciences will grant GE HealthCare the United States rights to FAPI-74, an experimental PET imaging agent in late-stage testing for detecting cancer, of which GE HealthCare already owns rights outside the United States

Debatable claims

• ▪Consolidation in the radiopharmaceuticals industry will harm market competition
• ▪The high cost of radiopharmaceuticals is justified by their diagnostic accuracy